ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,580,758 | +163.4% | 112,994 | +151.1% | 0.07% | +140.0% |
Q2 2023 | $4,016,250 | -16.8% | 45,000 | 0.0% | 0.03% | -28.6% |
Q1 2023 | $4,824,900 | +7.2% | 45,000 | +15.1% | 0.04% | -27.6% |
Q2 2019 | $4,502,000 | -31.5% | 39,101 | -30.0% | 0.06% | -33.3% |
Q1 2019 | $6,577,000 | +930.9% | 55,878 | +520.9% | 0.09% | +1142.9% |
Q3 2018 | $638,000 | -74.2% | 9,000 | -75.8% | 0.01% | -68.2% |
Q2 2018 | $2,474,000 | +41.7% | 37,190 | +39.3% | 0.02% | +57.1% |
Q1 2018 | $1,746,000 | -49.6% | 26,700 | -69.1% | 0.01% | -50.0% |
Q4 2017 | $3,465,000 | -13.1% | 86,500 | -21.4% | 0.03% | -6.7% |
Q3 2017 | $3,988,000 | +236.0% | 110,000 | +64.0% | 0.03% | +114.3% |
Q3 2015 | $1,187,000 | -44.9% | 67,079 | -45.0% | 0.01% | +16.7% |
Q2 2015 | $2,154,000 | +24.2% | 121,880 | +21.9% | 0.01% | -50.0% |
Q1 2015 | $1,734,000 | – | 99,955 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |